Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5199MR)

This product GTTS-WQ5199MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5199MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1903MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ15312MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ15816MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ9305MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ12577MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ9033MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ11552MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ15078MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SSS-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW